Some coverage in...

Some coverage in Forbes

https://www.forbes.com/sites/juergeneckhardt/2024/02/22/how-animals-are-inspiring-potentially-life-saving-human-medicines/?sh=7a1409232e38

When QBiotics Group, an Australian life sciences company, began developing drug candidates for a group of rare cancers that affect the body’s connective tissues, known as soft tissue sarcomas, they turned to dogs. Just like humans, our canine friends can also develop soft tissue sarcomas underneath their skin, which can metastasize and spread with fatal consequences.


Canine tumors share many biological, genetic, and histologic features with their human tumor counterparts,” says Dr. Victoria Gordon, Executive Director and Co-Founder at QBiotics Group. “They retain the complexities of naturally occurring drug resistance, metastasis, and tumor-host immune reactions.”Studying soft tissue sarcomas in dogs has directly enabled QBiotics to hone the dosing and treatment regime for their lead molecule. As a result, the company has applied for Orphan Drug Designation with the Food and Drug Administration and is now recruiting for a Phase II clinical trial in soft tissue sarcoma patients, at the Memorial Sloan Kettering Cancer Center in New York.